Get started
Author

Olga V. Ponomarova

Observed names: O Ponomarova, O. Ponomarova, O.V. PONOMAROVA, O.V. Ponomarova, Olga Ponomarova, Ponomarova O., Ponomarova Olga
Observed institutions: Amgen (United States), Shupyk National Healthcare University of Ukraine, Institut za onkologiju i radiologiju Srbije, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Marienhospital Bottrop, City Clinical Oncology Center, Kyiv City Clinical Oncology Center, Vall d'Hebron Institute of Oncology
ORCID: 0000-0002-2466-3277
Observed ORCIDs: 0000-0002-2466-3277, 0000-0003-3508-6687
OpenAlex ID: A5058350648
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · Tony S K Mok, Yi-Long Wu, et al. · The Lancet · 3,312
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · Javier Cortes, David W Cescon, et al. · The Lancet · 1,810
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
2015 · M. Schuler, J.C.-H. Yang, et al. · Annals of Oncology · 131
PDF
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
2009 · A. Brufsky, I. Bondarenko, et al. · Cancer Research · 67
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer
2016 · David E. Gerber, David R. Spigel, et al. · Clinical Lung Cancer · 23
Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
2017 · G. von Minckwitz, O. Ponomarova, et al. · Annals of Oncology · 16
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.
2013 · Mikhail Shtivelband, David R. Spigel, et al. · Journal of Clinical Oncology · 10
Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine
2022 · Anastasiia Samusieva, Svitlana Serga, et al. · Breast Cancer Research and Treatment · 5
Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research
2025 · Ielizaveta Gorodetska, Anastasiia Samusieva, et al. · The Breast Journal · 4
PDF
Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications
2018 · H.C. Kolberg, Z. Tomasevic, et al. · European Journal of Cancer · 3
An association of XRCC1 codon 399 polymorphism (RS25487) with bladder and prostate cancer susceptibility in the Ukrainian population
2020 · Yaroslava Mishchuk-Reka, Yevhenia Kharkivska, et al. · Meta Gene · 2
Vinflunine (Vfl) Plus Capecitabine (Cape) for Advanced Breast Cancer (Abc) Previously Treated with or Resistant to Anthracycline and Resistant to Taxane : a Phase 3 Study Versus Capecitabine
2014 · M. Martin, Y. Demidchik, et al. · Annals of Oncology · 2
Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.
2014 · Matti S. Aapro, Yuri Demidchik, et al. · Journal of Clinical Oncology · 2
The reduction of two BRCA1 gene mutations frequencies in ovarian cancer patients from Ukraine
2021 · Ielizaveta Gorodetska, Mariia Inomistova, et al. · Meta Gene · 1
Application of Infrared Spectroscopy in the Differential Diagnosis of Tumor Diseases of the Mammary Gland
2019 · N.Yu. PERSHKO, O.Ye. LEVCHENKO, et al. · Experimental and Clinical Physiology and Biochemistry · 1
PDF
Abstract P6-17-21: Matching the critical function of the biosimilar ABP 980 and trastuzumab: Totality of evidence and scientific justification for extrapolation across trastuzumab indications
2019 · H-C Kolberg, MA Colleoni, et al. · Cancer Research · 1
485 Influence of disease free interval on the efficacy of capecitabine-bevacizumab for HER2-negative metastatic breast cancer (MBC) in the RIBBON-1 trial
2010 · A. Brufsky, O. Ponomarova, et al. · European Journal of Cancer Supplements · 1
Study of Predictive Value of Rad51 Expression for the Effectiveness of Platinum-based Therapy of High-grade Serous Ovarian Carcinoma
2026 · P. Gordiichuk, M. Doronina, et al. · Experimental Oncology
PDF
Breast cancer in Ukraine: clinics and diagnostics. Current status and prospects of diagnostics (lecture)
2025 · A. Samusieva, V. Zaichuk, et al. · Experimental and Clinical Medicine
PDF
Planning and use of oncoplastic surgery for breast cancer
2023 · A.A. Samusieva, R.V. Liubota, et al. · Reproductive health of woman
PDF
Predicative significance of topoisomerase 2 alpha in patients with triple-negative breast cancer
2022 · Samusieva A., Ponomarova O., et al. · Zenodo (CERN European Organization for Nuclear Research)
PDF
Role of vitamin D on risks of breast cancer (Review)
2020 · A.A. Samusieva, O.V. Ponomarova, et al. · HEALTH OF WOMAN
Matching the critical function of the biosimilar ABP 980 and Trastuzumab
2019 · HC Kolberg, MA Colleoni, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
早期乳癌におけるバイオシミラー薬abp980とトラスツズマブの第iii相比較試験(lilac)結果:適応症外挿の正当性根拠
2018 · Yasuhiro Fujiwara, Tomasevic Zorica, et al. · 日本臨床腫瘍学会学術集会(CD-ROM)
Works count: 24
Citation count: 5,390
H-index: 7
I10-index: 7
Year
Topic
Type